BRPI0212215B8 - compostos de ciclopenta[g]quinazolina anticâncer, uso dos mesmos para o tratamento de câncer e composição farmacêutica compreendendo dito composto - Google Patents

compostos de ciclopenta[g]quinazolina anticâncer, uso dos mesmos para o tratamento de câncer e composição farmacêutica compreendendo dito composto

Info

Publication number
BRPI0212215B8
BRPI0212215B8 BRPI0212215A BRPI0212215A BRPI0212215B8 BR PI0212215 B8 BRPI0212215 B8 BR PI0212215B8 BR PI0212215 A BRPI0212215 A BR PI0212215A BR PI0212215 A BRPI0212215 A BR PI0212215A BR PI0212215 B8 BRPI0212215 B8 BR PI0212215B8
Authority
BR
Brazil
Prior art keywords
cyclopenta
alkyl
quinazoline
cancer
compound
Prior art date
Application number
BRPI0212215A
Other languages
English (en)
Inventor
Lesley Jackman Ann
Bavetsias Vassilios
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121151A external-priority patent/GB0121151D0/en
Priority claimed from GB0129387A external-priority patent/GB0129387D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of BR0212215A publication Critical patent/BR0212215A/pt
Publication of BRPI0212215B1 publication Critical patent/BRPI0212215B1/pt
Publication of BRPI0212215B8 publication Critical patent/BRPI0212215B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

compostos de ciclopenta [g] quinazolina anticâncer. as ciclopenta [g] quinazolinas da fórmula (i) : - em que: a é um grupo or ou nr0r1 em que r0 e r1 são cada um independentemente hidrogênio, alquila de c1-4, alquenila de c3-c4, alquinila de c3-4, hidróxialquila de c2-4, halogenoalquila de c2-4 ou cianoalquila de c1-4, ou r0 e r1 juntamente com o n intermediário formam um anel heterocíclico de cinco ou seis elementos; p é um número inteiro na faixa 1 a 4; r2 é hidrogênio, alquila de c1-4, alquenila de c3-4, alquinila de c3-4, hidróxialquila de c2-4, halogenoalquila de c2-4 ou cianoalquila de c1-4; ar1 é fenileno, tiofenodiíla, tiazoldiíla, piridinadiíla ou pirimidinadiíla que pode opcionalmente conter um ou dois substituintes selecionados a partir de halogeno, hidróxi, amino, nitro, ciano, triflúormetila, alquila de c1-4 e alcóxi de c1-4; e r3 é um grupo de uma das seguintes fórmulas: -a1-ar2-a2 -y1, -a5-con (r) ch (y4) y5, -a8-x-ar4, e os seus sais ou ésteres farmaceuticamente aceitáveis são de valor terapêutico, particularmente no tratamento de câncer.
BRPI0212215A 2001-08-31 2002-08-30 compostos de ciclopenta[g]quinazolina anticâncer, uso dos mesmos para o tratamento de câncer e composição farmacêutica compreendendo dito composto BRPI0212215B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0121151A GB0121151D0 (en) 2001-08-31 2001-08-31 Anti-cancer compounds
GB0121151.5 2001-08-31
GB0129387A GB0129387D0 (en) 2001-12-07 2001-12-07 Anti-cancer compounds
GB0129387.7 2001-12-07
US34025301P 2001-12-18 2001-12-18
US60/340,253 2001-12-18
PCT/GB2002/003979 WO2003020748A1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds

Publications (3)

Publication Number Publication Date
BR0212215A BR0212215A (pt) 2004-09-21
BRPI0212215B1 BRPI0212215B1 (pt) 2019-02-19
BRPI0212215B8 true BRPI0212215B8 (pt) 2021-07-27

Family

ID=27256270

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212215A BRPI0212215B8 (pt) 2001-08-31 2002-08-30 compostos de ciclopenta[g]quinazolina anticâncer, uso dos mesmos para o tratamento de câncer e composição farmacêutica compreendendo dito composto

Country Status (15)

Country Link
US (6) US7297701B2 (pt)
EP (3) EP2311850A1 (pt)
JP (1) JP4328202B2 (pt)
KR (2) KR100983962B1 (pt)
AT (1) ATE483722T1 (pt)
AU (1) AU2002321576B2 (pt)
BR (1) BRPI0212215B8 (pt)
CA (1) CA2458813C (pt)
CY (1) CY1111078T1 (pt)
DE (1) DE60237902D1 (pt)
DK (1) DK1421105T3 (pt)
MX (1) MXPA04001905A (pt)
PT (1) PT1421105E (pt)
WO (1) WO2003020748A1 (pt)
ZA (1) ZA200401587B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237902D1 (de) * 2001-08-31 2010-11-18 Btg Int Ltd ANTIKREBS-CYCLOPENTAiG CHINAZOLINE-DERIVATE
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
DK2032701T3 (da) 2006-06-23 2014-02-10 Alethia Biotherapeutics Inc Polynukleotider og polypeptider, der er inddraget i cancer
JP5599773B2 (ja) * 2008-03-18 2014-10-01 ビーティージー・インターナショナル・リミテッド リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体
MX336869B (es) 2008-11-03 2016-02-04 Alethia Biotherapeutics Inc Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
CA2804889A1 (en) 2010-07-19 2012-01-26 Onyx Pharmaceuticals, Inc. Synthesis of cyclopentaquinazolines
SG191269A1 (en) * 2010-12-22 2013-07-31 Onyx Pharma Inc Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (g) quinazoline trisodium salt
HUE045943T2 (hu) 2011-03-31 2020-02-28 Adc Therapeutics Sa Veseasszociált antigén 1 és antigénkötõ fragmensei elleni antitestek
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
GB201707864D0 (en) * 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069468D1 (en) 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9223352D0 (en) 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
JPH1166841A (ja) * 1997-08-22 1999-03-09 Mitsubishi Electric Corp 半導体記憶装置
KR100303775B1 (ko) * 1998-10-28 2001-09-24 박종섭 디디알 에스디램에서 데이터스트로브신호를 제어하기 위한 방법및 장치
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
JP3416083B2 (ja) * 1999-08-31 2003-06-16 株式会社日立製作所 半導体装置
JP2002007200A (ja) * 2000-06-16 2002-01-11 Nec Corp メモリ制御装置及び動作切替方法並びにインターフェース装置、半導体集積チップ、記録媒体
WO2003020300A1 (en) 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
DE60237902D1 (de) * 2001-08-31 2010-11-18 Btg Int Ltd ANTIKREBS-CYCLOPENTAiG CHINAZOLINE-DERIVATE
KR100568546B1 (ko) * 2004-10-19 2006-04-07 삼성전자주식회사 메모리 시스템, 반도체 메모리 장치, 및 이 시스템과장치의 출력 데이터 스트로우브 신호 발생 방법
KR100755371B1 (ko) * 2005-05-03 2007-09-04 삼성전자주식회사 반도체 메모리 장치 및 이 장치의 데이터 스트로우브 신호발생방법

Also Published As

Publication number Publication date
BRPI0212215B1 (pt) 2019-02-19
EP2332962A1 (en) 2011-06-15
US7863284B2 (en) 2011-01-04
US8486955B2 (en) 2013-07-16
EP1421105A1 (en) 2004-05-26
US20090023760A1 (en) 2009-01-22
US20100056551A1 (en) 2010-03-04
ATE483722T1 (de) 2010-10-15
US7705006B2 (en) 2010-04-27
DK1421105T3 (da) 2010-11-29
DE60237902D1 (de) 2010-11-18
CA2458813C (en) 2011-11-01
EP2311850A1 (en) 2011-04-20
JP2005509600A (ja) 2005-04-14
US20040242606A1 (en) 2004-12-02
US20080015206A1 (en) 2008-01-17
JP4328202B2 (ja) 2009-09-09
KR100983962B1 (ko) 2010-09-27
US20100273817A1 (en) 2010-10-28
CY1111078T1 (el) 2015-06-11
US8552016B2 (en) 2013-10-08
BR0212215A (pt) 2004-09-21
US7297701B2 (en) 2007-11-20
MXPA04001905A (es) 2005-04-19
PT1421105E (pt) 2010-12-07
EP1421105B1 (en) 2010-10-06
US8063056B2 (en) 2011-11-22
WO2003020748A1 (en) 2003-03-13
US20100216824A1 (en) 2010-08-26
ZA200401587B (en) 2005-05-25
CA2458813A1 (en) 2003-03-13
KR20040044511A (ko) 2004-05-28
AU2002321576B2 (en) 2008-09-11
KR20100043294A (ko) 2010-04-28

Similar Documents

Publication Publication Date Title
CY1111078T1 (el) Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινων
CY1112143T1 (el) Χρηση παραγωγων kykλοπenta[g]kinαζολινης για θεραπεια καρκινου
AR012660A1 (es) Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon.
EA200200546A1 (ru) Устойчивый полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способы его получения и фармацевтические применения
PT1104760E (pt) Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
ATE449083T1 (de) Chinazolin-derivate und ihre verwendung als arzneimittel
EP1243582A4 (en) CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
DE69720965D1 (de) Chinazolinderivate und deren verwendung als vegf hemmer
ATE294796T1 (de) Chinazolin derivate
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
AR039203A1 (es) Derivados de quinazolina
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
BG106526A (en) Therapeutic quinazoline derivatives
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
CO6382111A2 (es) Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia
PT1104759E (pt) Compostos heteroaril-fenil-pirazole como agentes anti-inflamatorios e analgesicos
AR035756A1 (es) Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos
TW200744575A (en) Methods of treating epileptogenesis
CA2302943A1 (en) Phthalazine compounds and therapeutic agents for erectile dysfunction
NO20033800L (no) Karbamidforbindelser for bruk ved prevensjon eller terapi av angstlidelser
BRPI0418375A (pt) derivados de diaza-espiropiperidina
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias
TW200635898A (en) Benzoyl-tetrahydropyridine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: BTG INTERNATIONAL LIMITED (GB)

Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110103158/RJ DE 04/10/2011.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2259 DE 22/04/2014

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2002, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 30/08/2022